Oita University
Interleukin-12 immunotherapy hastens the demise of solid tumors
Published in Biotech Law Weekly, August 26th, 2005
"A conventional dendritic cell (DC)-based immunotherapy has been tested clinically for treatment of patients with advanced cancer but requires modification to further improve the clinical results. In this study, we evaluated the in vivo antitumor effects of DC therapy, non-viral-mediated interleukin (IL)-12 gene therapy, and a combination of the two in a murine bilateral subcutaneous tumor model," scientists in Japan report.
"DC therapy alone and IL-12 gene therapy alone suppressed tumor growth at the injected sites. However, the antitumor effect on the distant contralateral tumor was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
Source: Biotech Law Weekly (2005-08-26)
More Articles from Biotech Law Weekly
- Abbott Laboratories
Pharma firm reaches agreement with Brazilian government for AIDS drug - BSD Medical Corp.
Patent to be issued for new device to optimize radiation treatments - CryoLife, Inc.
Biomaterials company to settle shareholder suits - Cyberonics, Inc.
VNS maker announces revised long-term sales outlook and guidance for fiscal 2006 - CytoGenix, Inc.
Company files U.S. patent application for family of DNA antimicrobial agents - DNAPrint genomics, Inc.
Genomics company launches new corporate marketing and product branding campaign - More from this issue of Biotech Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
